Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Best Practice & Research. Clinical Haematology|July 23, 2025
Cytokines and immune effector cell therapyAlexandra Haugh, Matthew J Frigault
International Immunology|March 30, 2016
Chimeric antigen receptor-modified T cells strike backMatthew J Frigault, Marcela V Maus
Blood|December 24, 2011
Predicting cytokine storms: it's about densityMatthew J Frigault, Carl H June
The Journal of Clinical Investigation|April 3, 2020
State of the art in CAR T cell therapy for CD19+ B cell malignanciesMatthew J Frigault, Marcela V Maus
Blood|February 1, 2024
Two years later: CD19 CAR-T going the distanceEli P Darnell, Matthew J Frigault
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2017
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as TherapyFelipe Bedoya, Matthew J Frigault, Marcela V Maus
Frontiers in Oncology|May 7, 2019
CAR-Based Approaches to Cutaneous T-Cell LymphomaIrene Scarfò, Matthew J Frigault, Marcela V Maus
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2020
Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell TherapiesMark B Leick, Marcela V Maus, Matthew J Frigault
Hematological Oncology|September 8, 2023
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapyHazim S Ababneh, Matthew J Frigault, Chirayu G Patel
Expert Opinion on Pharmacotherapy|April 8, 2024
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapyZandra E Walton, Matthew J Frigault, Marcela V Maus
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|July 23, 2025
Cytokines and immune effector cell therapyAlexandra Haugh, Matthew J Frigault
International Immunology|March 30, 2016
Chimeric antigen receptor-modified T cells strike backMatthew J Frigault, Marcela V Maus
Blood|December 24, 2011
Predicting cytokine storms: it's about densityMatthew J Frigault, Carl H June
The Journal of Clinical Investigation|April 3, 2020
State of the art in CAR T cell therapy for CD19+ B cell malignanciesMatthew J Frigault, Marcela V Maus
Blood|February 1, 2024
Two years later: CD19 CAR-T going the distanceEli P Darnell, Matthew J Frigault
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2017
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as TherapyFelipe Bedoya, Matthew J Frigault, Marcela V Maus
Frontiers in Oncology|May 7, 2019
CAR-Based Approaches to Cutaneous T-Cell LymphomaIrene Scarfò, Matthew J Frigault, Marcela V Maus
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2020
Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell TherapiesMark B Leick, Marcela V Maus, Matthew J Frigault
Hematological Oncology|September 8, 2023
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapyHazim S Ababneh, Matthew J Frigault, Chirayu G Patel
Expert Opinion on Pharmacotherapy|April 8, 2024
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapyZandra E Walton, Matthew J Frigault, Marcela V Maus
Pageof 12